Fragment 176-191: A Synopsis of the Research Topics

Fragment 176-191 peptide is a brief section of growth hormone (hGH) frequently called the “lipolytic fragment.” The term “Fragment 176-191” was developed as a result of preliminary research conducted on animal models, which suggested that this particular sequence had the potential to improve fat metabolism in genetically altered mice that are obese. The presentation of growth hormone (hGH) may have many unintended physiological consequences, including inhibiting glucose metabolism, modifying insulin sensitivity, stimulating long bone development, and increasing insulin-like growth factor-1 (IGF-1) levels. Extensive research on animals has led researchers to speculate that the synthetic fragment may improve the lipolytic effects of hGH possibly without producing the same ancillary impacts.

Fragment 176-191 Peptide and Weight

Studies suggest that the capacity of Frag 176-191 to enhance the synthesis of beta-3 adrenergic receptors, also known as 3-AR or ADRB3, is hypothesized to be the source of the peptide’s potential in supporting fat loss. Research suggests that the agonist activity of the Fragment 176-191 peptide, when it interacted with ADRB3, seemed to increase fat burning in adipose tissue directly, and it may also activate thermogenesis in skeletal muscle. 

Certain studies suggest that genetically modified mice deficient in ADRB3 may be immune to the effects of growth hormone (hGH) / Fragment 176-191. A three-week presentation with Fragment 176-191 seemed to reduce the weight carried by obese mice by as much as fifty percent, as suggested by the findings of one experimental investigation. Interestingly, throughout the same presentation period, the peptide only seemed to influence weight loss in obese mice but not in lean animals. These findings imply that additional routes may be engaged in energy homeostasis that can preserve fat reserve in thin mice by bypassing the ADRB3 pathway. These pathways may be involved in energy homeostasis.

Fragment 176-191 Peptide and Blood Sugar Levels

The C terminal end of growth hormone (hGH) is generally considered to be responsible for inducing hypoglycemia (low blood sugar) levels in the bodies of mice. The results of a screening that included at least six distinct fragments produced from the C terminal portion of hGH suggest that the synthetic derivative of hGH known as Fragment 176-191 may be the most successful in bringing down the amount of sugar in the blood. The primary focus should be keeping insulin levels high in the blood plasma to perform the secondary function of lowering blood sugar. Studies in Fragment 176-191 suggested it may support this action.

Fragment 176-191 Peptide and Cartilage

The findings of the experiments described in Frag 176-191 point to its potential to stimulate cartilage regeneration. Researchers looking into synthetic peptides have hypothesized that they might promote cartilage regeneration similarly to hyaluronic acid. The findings of several studies on rabbits suggest that the presentation of Fragment 176-191 every week seemed to promote cartilage formation (within the parameters of the laboratory), and the combination of this with hyaluronic acid (HA) looked to be even more successful.

Fragment 176-191 Peptide: A Synopsis of the Research Topics 

The primary focus of the study on Fragment 176-191 is on the function it may play in the breakdown of fat and the process of losing weight. As a result, more study has been conducted on the mechanism that maintains energy balance in the body. Fragment 176-191’s influence on the regeneration of cartilage and connective tissue is one of the secondary areas of study.

The findings of the meta-analysis suggest that the peptide may have the capacity to give the same positive results associated with hGH supplementation without necessarily activating certain adverse consequences associated with hGH. The research paves the path for more in-depth knowledge of energy homeostasis, targeted fat metabolism, and the many ways it may be manipulated.

It is essential to understand that growth hormone (hGH) promotes muscle growth and development, but the catabolic nature of Fragment 176-191 peptides cannot be overstated. The findings of many studies suggest the peptide seems to stimulate lipolysis in adipocytes possibly without inducing acromegaly or other effects often associated with hGH. It has also been suggested through experimental mouse models that the peptide does not appear to stimulate the growth of cells.

Fragment 176-191 for sale can only be used by academics or licensed professionals in laboratory settings. This compound has not been approved for human consumption. Therefore, any bodily introduction is prohibited.

References

[i] Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022 Jun 27;16:1963-1974. doi: 10.2147/DDDT.S367586. PMID: 35783198; PMCID: PMC9249349.

[ii] Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.

[iii] Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000 Sep;279(3):E501-7. doi: 10.1152/ajpendo.2000.279.3.E501. PMID: 10950816.

[iv] Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978 May;234(5):E521-6. doi: 10.1152/ajpendo.1978.234.5.E521. PMID: 645904.

[v] Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.